Submit when the Science is Done
Learn how to make agentic AI trustworthy in clinical trials, with your experts in control, always.
We have come to the final article on AI and the Economics of Time.
In this series we have explored time as a strategic asset, how acceleration creates value, how releasing capacity creates opportunity, and how uncertainty gives value back. We also showed how provenance and traceability can reduce uncertainty.
This leaves us with one final question:
…..“What is trust actually worth?
Imagine two pharmaceutical companies using a similar AI technology:
….. both reduce document preparation time by approximately 40%.
….. both generate high-quality draft content in a fraction of the previous time
On paper, the productivity gains appear identical, but there is one crucial difference.
Organisation A needs four weeks and multiple resources for validation of the AI output before they are comfortable progressing.
Organisation B can establish confidence in the AI-generated output in one day.
Almost four weeks have been removed from the critical path. Those four weeks do not simply represent four weeks of labour saved. They potentially move everything that follows: the next analysis, the next submission milestone and, ultimately, the date at which a medicine reaches patients and begins generating revenue.
The productivity gain may be the same. The economic value is not.
This difference is the Trust Premium: the additional economic value created when confidence in an AI-generated answer allows an organisation to act sooner.
Where does this confidence come from?
As we saw in Article 3, AI is only as good as the context in which it operates. The AI model provides the automation capability. The infrastructure provides the context, connecting the underlying information and maintaining its provenance so that outputs can be immediately understood and verified.
In clinical development keeping the “human in the loop” is important. Human experts provide the scientific judgement, challenge, and final approval.
When the context and supporting evidence are readily available, reviewers can spend less time reconstructing how an answer was reached and more time applying the expertise and judgement for which they are responsible.
The goal is not to remove human review from the critical path; it is to submit after the science is done, with the ultimate goal to enable real-time regulatory review.
This is why infrastructure is not simply a technical consideration in AI deployment, but it is part of the economic architecture of AI.
Without the right context, AI may generate answers quickly, but uncertainty can give the time back. With the right infrastructure and expert oversight, speed converts into confident action.
This takes us beyond the conventional business case.
We typically measure hours saved, tasks automated, documents generated, people redeployed. What if we also measure how much sooner the organisation was able to make a decision?
This is the decision velocity – the speed at which an organisation can move from AI-generated information, through expert review and approval, to confident action.
In drug development it matters enormously:
…..a faster decision can bring forward the next analysis
…..an earlier analysis can bring forward a submission
…..an earlier submission can bring forward approval
…..an earlier approval can bring forward patient access and revenue
Traditional productivity measures tell us how quickly the AI worked. Decision velocity tells us how quickly the organization can move as a result.
As AI becomes more widely available, access to powerful models alone will become less differentiating. Two organisations may use the same model. They may generate the same analysis in the same amount of time. They may achieve the same productivity improvement. But if one has the infrastructure that allows it to establish confidence days or weeks earlier, the economic outcome can be quite different.
This creates a new way of thinking about competitive advantage in AI. “Who has the best AI” may increasingly become “Who has created the environment in which AI can be trusted and acted upon the fastest”.
Across these four articles we have explored a unique way of thinking about the economics of AI.
We started with the traditional productivity questions. Those questions still matter, but they do not capture the full economic opportunity.
The Economics of Time leads us to four broader conclusions:
AI does not create value in isolation. The model provides automation capability. The infrastructure creates trusted context, ensuring the results are grounded in evidence, expediting review and enabling confidence. Human oversight turns that confidence into judgement and action.
Together they determine how effectively the speed of AI can be translated into economic value.
So perhaps the future winners in AI will not simply be the organisations with the most powerful models. They will be the organisations that create a trusted context, allowing users to move from information to decision, and from decision to action, faster than anyone else.
In the Economics of Time, generating answers faster is only the beginning. The real gain comes from an environment which turns speed into trust, and trust into action!
Verisian unifies every document, specification, code, dataset, and result into a fully deterministic, reproducible, and traceable system. This is the infrastructure our AI runs on.
If you would like to explore how Verisian could speed your products to market, let’s chat.
Carol Collins has over 30 years leadership experience in the global Life Sciences and Healthcare industry, with 20 years in clinical development. Throughout her career she has had a key focus on innovation and transformation to accelerate outcomes, create value and bring life-saving medicines to patients. She is a strategic advisor to Verisian.
See Verisian in action. Share a few details and we’ll be in touch to schedule your demo.
Your request has been received. A member of the Verisian team will contact you shortly to arrange a demo.
